Category: MS Drug Therapies

New Data for Genentech’s Ocrevus (Ocrelizumab) Show Benefit in Disability Progression and Cognitive Decline in Both Secondary Progressive and Primary Progressive Multiple Sclerosis

  75% of patients with secondary progressive multiple sclerosis (SPMS) and primary progressive MS (PPMS) achieved no evidence of progression…

Stuart Schlossman

About BAFIERTAM™ (monomethyl fumarate) treatment, for Multiple Sclerosis

Banner Life Sciences Announces BAFIERTAM, a Novel Oral Fumarate Treatment for Relapsing Forms of Multiple Sclerosis, is available in the…

Stuart Schlossman

3D Showing of Mayzent Binding to Receptor Could Advance Treatments

 by Steve Bryson PhD | March 18, 2022 For the first time, researchers have brought to light the precise three-dimensional structure of Mayzent (siponimod) as…

Stuart Schlossman

#ACTRIMS2022 – Ublituximab Eases Brain Lesions Better Than Aubagio

 The experimental medication Ublituximab significantly reduces the number of new brain lesions with severe nerve cell degeneration in people with relapsing multiple…

Stuart Schlossman

Frequently Asked Questions ( FAQ’s ) : Generic, Biologic and Biosimilar – Medications

February   2022 What is a generic medication? A generic medication is a product that is equivalent to a brand-name medication whose patent protections…

Stuart Schlossman

RSVP for MS Webinars on February 8th & 9th for: Pelvic Floor Rehabilitation; Strengthening & Stretching; MS Symptoms Management, Treatment updates and more…

  For February 8th  – This presentation on Pelvic Floor & Bladder Issues in MS – Understanding avenues of therapy…

Stuart Schlossman

Sweden, Like France, OKs Start of Masitinib Trial in Progressive MS

 Feb. 7th, 2022 The Swedish Medical Products Agency has approved AB Science’s request to launch in the country a confirmatory…

Stuart Schlossman

Answering Viewers Questions: Highly Effective Multiple Sclerosis Medications

  Click to Subscribe for the MS Beacon eNewsletter and MS educational events Visit our MS Learning Channel on YouTube:…

Stuart Schlossman

Novartis announces U.S. Court of Appeals for the Federal Circuit (CAFC) upholds validity of Gilenya® (fingolimod) dosage regimen patent

 January 4, 2022 —  Basel, January 4, 2022 — Today, Novartis announced that the U.S. Court of Appeals for the Federal…

Stuart Schlossman

Study: Anti-CD20 Therapies, Gilenya Lower Efficacy of COVID-19 Vaccines

  Certain treatments for multiple sclerosis (MS) — specifically, anti-CD20 antibody therapies and Gilenya (fingolimod) — are likely to reduce the effectiveness of vaccines…

Stuart Schlossman

Categories

Latest Blog Posts